StemVax Therapeutics, https://stemvax.com, has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient’s tumor. Our platform technology focuses on enhancing the patient’s immune cells to fight their unique cancer by utilizing the antigens specific to the patient’s tumor. Our unique combination of TLR adjuvants, in addition to the tumor’s antigens, obtained from the patient, promotes an enhanced immune response shown to be more efficacious in pre-clinical studies when compared to previous generations of the therapy. TLR-AD1 therapy is at the Investigational New Drug (IND) filing stage and StemVax Therapeutics seeks to start human clinical trials after obtaining IND approval.